207 related articles for article (PubMed ID: 19548455)
21. [The influence of interleukin-6 and tumor necrosis factor alpha gene polymorphisms on bone mineral density in postmenopausal women].
Kusek J; Seremak-Mrozikiewicz A; Drews K; Mikołajczak P; Czerny B; Maciejewska M; Bogacz A; Derebecka-Hołysz N; Barlik M; Mrozikiewicz PM
Ginekol Pol; 2008 Jun; 79(6):426-31. PubMed ID: 18652131
[TBL] [Abstract][Full Text] [Related]
22. Association between osteoprotegerin genetic variants and osteoporosis in Chinese postmenopausal women.
Yu F; Huang X; Miao J; Guo L; Tao D
Endocr J; 2013; 60(12):1303-7. PubMed ID: 24067544
[TBL] [Abstract][Full Text] [Related]
23. The influence of g.19124G>a genetic polymorphism in the OPG gene on bone mineral density in Chinese women.
Zhu J; Luo Z; Cao Y; Yu M; Peng J; Huang D
Genet Test Mol Biomarkers; 2013 Sep; 17(9):696-9. PubMed ID: 23837846
[TBL] [Abstract][Full Text] [Related]
24. -643C > T RANKL gene polymorphism is associated with osteoporosis in Tunisian postmenopausal women.
Sassi R; Sahli H; Cheour E; Sellami S; El Gaaied ABA
Climacteric; 2017 Aug; 20(4):374-378. PubMed ID: 28453307
[TBL] [Abstract][Full Text] [Related]
25. Association between g.19163A>G and g.23298T>C genetic variants of the osteoprotegerin gene and bone mineral density in Chinese women.
Liu S; Yi Z; Ling M; Shi J
Hormones (Athens); 2013; 12(4):578-83. PubMed ID: 24457406
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women.
Tu P; Duan P; Zhang RS; Xu DB; Wang Y; Wu HP; Liu YH; Si L
Osteoporos Int; 2015 Jan; 26(1):179-85. PubMed ID: 25138264
[TBL] [Abstract][Full Text] [Related]
27. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
[TBL] [Abstract][Full Text] [Related]
28. Association of
Abdi S; Binbaz RA; Mohammed AK; Ansari MGA; Wani K; Amer OE; Alnaami AM; Aljohani N; Al-Daghri NM
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572979
[TBL] [Abstract][Full Text] [Related]
29. Association of the g.19074G>A genetic variant in the osteoprotegerin gene with bone mineral density in Chinese postmenopausal women.
Zhang YD; Zhang Z; Zhou NF; Jia WT; Cheng XG; Wei XJ
Genet Mol Res; 2014 Aug; 13(3):6646-52. PubMed ID: 25177945
[TBL] [Abstract][Full Text] [Related]
30. VDR, RANKL and OPG polymorphisms as possible predisposing cofactors of postmenopausal osteoporosis: explorative study in Italian population.
Mamolini E; Cervellati C; Greco P; Carrieri A; Massari L; Crivellari I; Scapoli C; Bonaccorsi G
Gynecol Endocrinol; 2017 Dec; 33(12):937-941. PubMed ID: 28488893
[TBL] [Abstract][Full Text] [Related]
31. Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression.
Takács I; Lazáry A; Kósa JP; Kiss J; Balla B; Nagy Z; Bácsi K; Speer G; Lakatos P
Eur J Endocrinol; 2010 Feb; 162(2):423-31. PubMed ID: 19934266
[TBL] [Abstract][Full Text] [Related]
32. [Association between Val80 polymorphism of the CYP19 gene, A163G polymorphism of the OPG gene and bone mineral density in post-menopausal Chinese women].
Geng L; Yao ZW; Luo JY; Han LL; Lu Q
Yi Chuan; 2007 Nov; 29(11):1345-50. PubMed ID: 17989043
[TBL] [Abstract][Full Text] [Related]
33. [Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis].
Wang C; He JW; Qin YJ; Zhang H; Hu WW; Liu YJ; Zhang ZL
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2958-62. PubMed ID: 20137703
[TBL] [Abstract][Full Text] [Related]
34. The ALUI calcitonin receptor gene polymorphism (TT) is associated with low bone mineral density and susceptibility to osteoporosis in postmenopausal women.
Tsai FJ; Chen WC; Chen HY; Tsai CH
Gynecol Obstet Invest; 2003; 55(2):82-7. PubMed ID: 12771454
[TBL] [Abstract][Full Text] [Related]
35. Correlation of vitamin D receptor gene (VDR) polymorphism with osteoporotic changes in Polish postmenopausal women.
Seremak-Mrozikiewicz A; Drews K; Mrozikiewicz PM; Bartkowiak-Wieczorek J; Marcinkowska M; Wawrzyniak A; Slomski R; Kalak R; Czerny B; Horst-Sikorska W
Neuro Endocrinol Lett; 2009; 30(4):540-6. PubMed ID: 20010502
[TBL] [Abstract][Full Text] [Related]
36. "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density".
Piedra M; García-Unzueta MT; Berja A; Paule B; Lavín BA; Valero C; Riancho JA; Amado JA
BMC Med Genet; 2011 Dec; 12():168. PubMed ID: 22185226
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms in period genes and bone response to hormone therapy in postmenopausal Korean women.
Kim J; Kim H; Ku SY; Suh CS; Kim JH; Kim JG
Climacteric; 2016; 19(1):85-90. PubMed ID: 26624862
[TBL] [Abstract][Full Text] [Related]
38. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis.
Chen HY; Chen WC; Hsu CM; Tsai FJ; Tsai CH
Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):73-8. PubMed ID: 15927351
[TBL] [Abstract][Full Text] [Related]
40. Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway.
Mencej-Bedrač S; Zupan J; Mlakar SJ; Zavratnik A; Preželj J; Marc J
Drug Metabol Drug Interact; 2014; 29(2):111-4. PubMed ID: 24615483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
